Improvement in Dysphagia Outcomes Following Clinical Target Volume Reduction in the De-ESCALaTE Study.


Journal

Clinical oncology (Royal College of Radiologists (Great Britain))
ISSN: 1433-2981
Titre abrégé: Clin Oncol (R Coll Radiol)
Pays: England
ID NLM: 9002902

Informations de publication

Date de publication:
12 2021
Historique:
received: 08 04 2021
revised: 02 06 2021
accepted: 14 07 2021
pubmed: 4 8 2021
medline: 26 11 2021
entrez: 3 8 2021
Statut: ppublish

Résumé

The De-ESCALaTE study showed an overall survival advantage for the administration of synchronous cisplatin chemotherapy with radiotherapy in low-risk oropharyngeal cancer when compared with synchronous cetuximab. During the trial, a radiotherapy quality assurance protocol amendment permitted centres to swap from the original radiotherapy contouring protocol (incorporating the whole oropharynx into the high-dose clinical target volume (CTV); anatomical protocol) to a protocol that incorporated the gross tumour volume with a 10 mm margin into the CTV (volumetric protocol). The purpose of this study was to examine both toxicity and tumour control related to this protocol amendment. Overall survival and recurrence at 2 years were used to compare tumour control in the two contouring cohorts. For toxicity, the cohorts were compared by both the number of severe (grades 3-5) and all grades acute and late toxicities. In addition, quality of life and swallowing were compared using EORTC-C30 and MD Anderson Dysphagia Inventory, respectively. Of 327 patients included in this study, 185 were contoured according to the anatomical protocol and 142 by the volumetric protocol. The two cohorts were well balanced, with the exception of significantly more patients in the anatomical cohort undergoing prophylactic feeding tube insertion (P < 0.001). With a minimum of 2 years of follow-up there was no significant difference in overall survival or recurrence between the two contouring protocols. Similarly, there was no significant difference in the rate of reported severe or all grades acute or late toxicity and no sustained significant difference in quality of life. However, there was a significant difference in favour of volumetric contouring in several domains of the MD Anderson Dysphagia Inventory questionnaire at 1 year, which persisted to 2 years in the dysphagia functional (P = 0.002), dysphagia physical (P = 0.009) and dysphagia overall function (P = 0.008) domains. In the context of the unplanned post-hoc analysis of a randomised trial, measurable improvement in long-term dysphagia has been shown following a reduction in the CTV. Further reductions in the CTV should be subject to similar scrutiny within the confines of a prospective study.

Identifiants

pubmed: 34340917
pii: S0936-6555(21)00268-5
doi: 10.1016/j.clon.2021.07.009
pii:
doi:

Substances chimiques

Cetuximab PQX0D8J21J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

795-803

Subventions

Organisme : Cancer Research UK
ID : 12834
Pays : United Kingdom

Informations de copyright

Copyright © 2021 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Auteurs

M Vreugdenhil (M)

Hall-Edwards Radiotherapy Research Group, Queen Elizabeth Hospital, Birmingham, UK.

C Fong (C)

Hall-Edwards Radiotherapy Research Group, Queen Elizabeth Hospital, Birmingham, UK.

G Iqbal (G)

Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.

T Roques (T)

Norfolk and Norwich University Hospitals, Norwich, UK.

M Evans (M)

Velindre University NHS Trust, Cardiff, UK.

N Palaniappan (N)

Velindre University NHS Trust, Cardiff, UK.

H Yang (H)

Addenbrooke's Hospital, Cambridge, UK.

L O'Toole (L)

Castle Hill Hospital, Cottingham, UK.

P Sanghera (P)

Hall-Edwards Radiotherapy Research Group, Queen Elizabeth Hospital, Birmingham, UK.

C Nutting (C)

Royal Marsden Hospital, London, UK.

B Foran (B)

Weston Park Hospital, Sheffield, UK.

M Sen (M)

St James' Institute of Oncology, Leeds, UK.

H Al Booz (H)

Bristol Haematology and Oncology Centre, Bristol, UK.

T Fulton-Lieuw (T)

Institute of Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK.

M Dalby (M)

Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.

J Dunn (J)

Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.

A Hartley (A)

Hall-Edwards Radiotherapy Research Group, Queen Elizabeth Hospital, Birmingham, UK. Electronic address: andrew.hartley@uhb.nhs.uk.

H Mehanna (H)

Institute of Head and Neck Studies and Education (InHANSE), University of Birmingham, Birmingham, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH